Lab study, 2022
Can we create a rat model of PMDD irritability and does treatment help?
Researchers created rats with PMDD symptoms and found that two drugs reduced a brain receptor linked to the symptoms.
What they did
Researchers created rats with PMDD symptoms using a resident-intruder stress test. They confirmed the model by controlling the estrous cycle. They measured brain chemicals and a brain receptor (GABRA4) before and after treatment with fluoxetine or Baixiangdan capsules.
What they found
The rats showed premenstrual irritability and anxiety similar to PMDD. During the premenstrual phase, progesterone and allopregnanolone decreased, serotonin increased, and GABA decreased. A brain receptor (GABRA4) was increased in multiple brain areas. Both drugs reduced GABRA4 levels.
What it means for you
The brain changes in the rat model match what might happen in PMDD. The treatments worked by changing one specific brain receptor. The main limit is this is an animal study, so results might not apply to women with PMDD.
About the study
- Original title
- Resident intruder paradigm-induced PMDD rat model of premenstrual irritability: behavioral phenotypes, drug intervention, and biomarkers
- Authors
- Gao M, Zhang H, Gao Z et al.
- Journal
- Aging
- Year
- 2022
- Study design
- Lab study
- What was tested
- Fluoxetine and Baixiangdan capsules
- Open access
- Yes
- Read the paper
- doi.org/10.18632/aging.204402
Original abstract
Background: Premenstrual dysphoric disorder (PMDD) is high in women of childbearing age with obvious premenstrual irritability. However, reliable animal models are still lacking. Materials and methods: PMDD rat model of premenstrual irritability was induced by the resident-intruder paradigm (RIP). Behavioral characteristics were determined by the aggressive behavior test, elevated plus maze, open-field test, and breast width measurement. The estrous cycle in rats was artificially manipulated by bilateral ovariectomy and exogenous hormone injection to verify the model phenotype's dependence on the estrous cycle. Fluoxetine and Baixiangdan capsules were administered by gavage to determine the symptom improvement effect of PMDD irritability. Biomarkers in serum and brain were detected using ELISA, and GABRA4 was detected in the brain by RT-PCR and Western blot. Results: Rat models demonstrated similar clinical characteristics as PMDD, such as premenstrual irritability and anxiety, and the above symptoms were estrous cycle-dependent. In addition, the levels of progesterone (P) and ALLO hormones decreased in the serum, hippocampus, amygdala, and frontal lobe in the NR phase. The contents of 5-HT in the brain were significantly increased, while NE and GABA contents were considerably reduced. Moreover, mRNA and protein expression of GABRA4 levels in model rats' amygdala, hippocampus, and frontal lobe were significantly increased, while drug intervention downregulated its expression in these tissues. Conclusion: Premenstrual irritability rat model of PMDD demonstrates a behavioral phenotype consistent with the clinical symptoms of PMDD and micro index. The increased levels of 5-HT, NE, and expression of GABRA4, as well as the decrease of GABA, P, and ALLO levels, may be critical biomarkers of the abnormal changes that occur during the pathogenesis of PMDD.
Reproduced under CC-BY.
Topics
Related studies
Review, 2018
What are the most effective treatments for premenstrual syndrome and PMDD?
Review, 2004
What is PMDD and how is it treated?
Review, 2004
How should doctors diagnose and treat PMS and PMDD?
Review, 2002
What treatments work best for PMS and PMDD?
Randomised trial, 1997
What is the difference between PMS and PMDD, and how should they be treated?
Cohort study, 2022
What are PMS and PMDD and how should they be diagnosed and treated?